We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ALUNBRIG (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ALUNBRIG
Date registered
Evaluation commenced
Decision date
Approval time
165 (255 working days)
Active ingredients
brigatinib
Registration type
EOI
Indication
ALUNBRIG (tablet) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).